PromoCell

PromoCell We are a leading biotechnology company who supports scientists worldwide with high-end human cell cul

At PromoCell, we help scientists do better research with a world-class portfolio of human primary, stem and blood cells as well as optimized cell culture media. With over 30 years of expertise, we are recognized globally for supplying scientists with the tools and support they need to do groundbreaking research. All our products comply with European biomedical conventions, ensuring human rights an

d donor privacy are always protected. Our ISO certifications demonstrate our absolute commitment to quality and our EXCiPACT™ GMP certification enables us to produce our cell culture media and reagents according to GMP standards as a manufacturer of pharmaceutical excipients. Each year 600 peer-reviewed publications feature PromoCell products. We operate in over 40 countries around the world, helping scientists with all of their research needs.

03/09/2026

Behind every breakthrough is a team that believes in yours.

At PromoCell, we’ve built something special: A Scientific Support team with over 30 years of experience across diverse research areas, ready to support your research journey from discovery to clinical application.

Whether you’re selecting the right primary cells, troubleshooting an unexpected result, or planning your next experiment, we’re here with:

- Technical product guidance tailored to your application
- Real-world troubleshooting from scientists who’ve been there
- Honest advice on product selection and availability

We don’t just provide high-quality cells and cell culture media — we partner with you to ensure you have the expert guidance you need to succeed.

Get expert support tailored to your workflow: https://eu1.hubs.ly/H0y2pzd0

Cancer stem cells (CSCs) drive tumor growth, resist therapy, and cause relapse, making them important targets for cancer...
01/09/2026

Cancer stem cells (CSCs) drive tumor growth, resist therapy, and cause relapse, making them important targets for cancer treatments.

Our comprehensive cell culture basics page covers everything you need to know about CSCs. We discuss their properties and markers, research challenges and solutions, CSC plasticity, drug resistance mechanisms, and therapeutic targeting strategies.

Explore the key concepts shaping CSC research: https://eu1.hubs.ly/H0xqNk10

Heading to Berlin for the 14th GSCN Conference. We’re excited to attend the German Stem Cell Network (GSCN) Conference, ...
26/08/2026

Heading to Berlin for the 14th GSCN Conference.

We’re excited to attend the German Stem Cell Network (GSCN) Conference, taking place September 9–11 in Berlin, Germany.

Join us and meet our experts Stephan Kuklinski and Tannishtha Saha. We’ll be showcasing our stem cell portfolio, designed to support your work, whether you're conducting basic research or advancing toward clinical manufacturing.

Visit us at booth #2 – Let’s connect to discuss your stem cell research goals and challenges, and discover how our solutions can help accelerate your work.
Stay tuned for more updates from Berlin.


German Stem Cell Network - GSCN - Deutsches Stammzellnetzwerk

Macrophages protect us, but when things go wrong, they can also make diseases worse.In neurodegenerative diseases like A...
20/08/2026

Macrophages protect us, but when things go wrong, they can also make diseases worse.

In neurodegenerative diseases like Alzheimer’s and Parkinson’s, macrophages help clear toxic protein aggregates. But when that clearance becomes impaired, they shift toward neuroinflammation, accelerating tissue damage.

In metabolic disorders like obesity and NAFLD, adipose tissue drives macrophages toward an M1 pro-inflammatory phenotype. This results in the release of inflammatory cytokines that promote insulin resistance and systemic inflammation.
And that’s not everything. Macrophages can promote chronic inflammation, influencing cancer, cardiovascular disease, and autoimmune diseases.

Learn more on our cell culture basics page: https://eu1.hubs.ly/H0xqvTX0

Planning to use primary cells or cell culture media in a commercial setting? Extended Right of Use (ERU) enables commerc...
19/08/2026

Planning to use primary cells or cell culture media in a commercial setting?

Extended Right of Use (ERU) enables commercial activities across the full development continuum – from cell line generation to assay validation, QC/testing, CRO services, and process development workflows. It also allows you to incorporate our products into third-party products or services.

If your work feeds into a commercial pipeline, you may need Extended Right of Use.

Find out where you stand: https://eu1.hubs.ly/H0xGYdh0

For our final summer reading recommendation for the month: How does the immune system distinguish self from non-self?“Th...
13/08/2026

For our final summer reading recommendation for the month: How does the immune system distinguish self from non-self?

“The Compatibility Gene” by Daniel Davis explores the science behind immune recognition – from organ transplantation to disease susceptibility. This insightful read highlights how genetic compatibility shapes immune responses and informs the development of modern therapies.
A fascinating perspective on the future of immunology and personalized medicine.

11/08/2026

How do you build reproducible assays using human preadipocytes?

Variability in preadipocyte assays can be reduced by selecting an appropriate cell model, optimizing expansion and differentiation conditions, and defining clear endpoints. Standardizing each of these steps helps you ensure your metabolic data are more reproducible and interpretable.

Watch the video on the key steps in reducing variability, and explore the full framework in our latest blog post: https://eu1.hubs.ly/H0xlg0C0

Continuing our summer reading series: What if we could redesign life itself to solve some of the biggest challenges in m...
04/08/2026

Continuing our summer reading series: What if we could redesign life itself to solve some of the biggest challenges in medicine?

“Regenesis” by George Church & Ed Regis explores the cutting edge of synthetic biology, from genome engineering to regenerative medicine.
This book dives into how advances in biotechnology could transform healthcare, enabling everything from lab-grown tissues to new approaches in disease treatment.
A forward-looking read that highlights the potential, and responsibility, of engineering biology.

What science book would you add to our list? Share it in the comments below.

How do inflammasomes get activated in different immune cells? Understanding the molecular mechanisms of inflammatory res...
28/07/2026

How do inflammasomes get activated in different immune cells? Understanding the molecular mechanisms of inflammatory responses is essential for developing targeted therapies for immune-related diseases.

In a study published in Nature Communications, researchers from the University of Tübingen, the University of Bonn, and collaborators engineered a variant of the NLRP3 inflammasome that forms smaller monomeric/dimeric assemblies instead of its typical decameric cage. Using THP-1 macrophage-like cells, they found that these smaller NLRP3 species can still form fully functional inflammasomes. In primary human macrophages and neutrophils from the same donors, the researchers found two parallel NLRP3 activation pathways (microtubule-dependent and microtubule-independent pathways), with microtubule-independent NLRP3 activation dominating in neutrophils.

Macrophage-based studies are often constrained by challenges in harvesting strongly adherent cells. These cells are highly sensitive to improper dissociation procedures, which can reduce cell viability and alter cell surface proteins, potentially compromising downstream experiments. Using our gentle, enzyme-free Macrophage Detachment Solution, the researchers were able to harvest viable, functional macrophages for downstream analysis.

Studies using functional primary macrophages underscore how working with viable, unaltered primary immune cells can reveal physiologically relevant mechanisms. They also open new angles for targeting inflammasome-driven diseases.

Mateo-Tórtola M, Hochheiser IV, Li G, et al. Non-decameric NLRP3 reveals a TGN/MTOC-distal pathway of inflammasome activation. Nat Commun. 2026;17(1):4866.
https://eu1.hubs.ly/H0x3ZFc0

Adresse

SickingenStr. 63/65
Heidelberg
69126

Öffnungszeiten

Montag 08:30 - 17:00
Dienstag 08:30 - 17:00
Mittwoch 08:30 - 17:00
Donnerstag 08:30 - 17:00
Freitag 08:30 - 17:00

Telefon

+496221649340

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von PromoCell erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Teilen